On Monday, Shares of Clorox Co (NYSE:CLX), gained 0.06% to $109.91.
Clorox Healthcare and the Alliance for the Prudent Use of Antibiotics, declared a new partnership to educate the healthcare community on comprehensive infection control practices to assist reduce the spread of infection in healthcare facilities. The Centers for Disease Control and Prevention (CDC) estimates that drug-resistant bacteria cause two million illnesses and about 23,000 deaths each year in the United States alone.1 Mathematical modeling comprised in its latest Vital Signs report shows that the spread of drug-resistant infections and Clostridium difficile (C. difficile) will improvement without immediate improvements in infection control and antibiotic prescribing. The report also states that if improved infection control practices and antibiotic stewardship efforts were adopted nationally, 619,000 infections and 37,000 deaths could be prevented over five years.
Clorox Healthcare and APUA share the belief that when armed with the right tools and information, infectious diseases physicians in partnership with other front-line healthcare providers and environmental services professionals can improve infection prevention practices to kill antibiotic-resistant organisms before infections can spread, protecting patients, staff and communities. The aim of this partnership is to jointly develop educational resources and materials that align with the following aims:
- Improvement awareness of antibiotic resistance.
- Prevent infections to prevent the spread of resistance.
“Ours is a natural alliance because strengthening health systems and clinical practice by cleaning, disinfection and process compliance reduces or prevents transmission of resistant bacteria. These are strategies that APUA champions globally and Clorox Healthcare assists realize,” said Stuart B. Levy, MD, President of APUA.
The Clorox Company manufactures and markets consumer and professional products worldwide. The company operates through four segments: Cleaning, Household, Lifestyle, and International. It offers laundry additives, counting bleach products under the Clorox, in addition to stain fighter and color booster products under the brand Clorox 2; and home care products under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands.
Shares of Premiere Global Services, Inc. (NYSE:PGI), inclined 0.22% to $13.77, during its last trading session.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Premiere Global Services, Inc. (PGI) concerning the acquisition by funds managed or advised by Siris Capital Group, LLC. Under the terms of the agreement, valued at about $1.0 billion, Premiere Global shareholders will only receive $14.00 per Premiere Global share owned.
Premiere Global Services, Inc. provides partnership software and services in North America, Europe, and the Asia Pacific. Its partnership platform enables business users and teams to connect and share ideas and manage projects with everywhere-access of the cloud technologies.
At the end of Monday’s trade, Shares of Turquoise Hill Resources Ltd (NYSE:TRQ), lost -1.00% to $2.97.
Turquoise Hill Resources, noted the signing by the Government of Mongolia of the request of the Multilateral Investment Guarantee Agency (MIGA) for host country approval (HCA) with respect to guarantees to be issued by MIGA in connection with the Oyu Tolgoi project financing. The signing of the HCA is a noteworthy milestone in the project financing timeline.
Turquoise Hill continues to progress the additional steps required to reach signing of project financing, which is predictable by the end of 2015.
Turquoise Hill Resources Ltd., together with its auxiliaries, operates as a mining company. Its principal material mineral resource property is the Oyu Tolgoi copper-gold mine located in the southern Mongolia.
Finally, Arrowhead Research Corp (NASDAQ:ARWR), ended its last trade with 2.19% gain, and closed at $6.54.
Arrowhead Research Corporation, declared that it has nominated ARC-HIF2 as its first therapeutic candidate delivered using a new Dynamic Polyconjugate (DPC) designed to target tissues outside of the liver. Arrowhead believes that ARC-HIF2, which uses RNA interference to silence transcription factor hypoxia-inducible factor 2α (HIF-2α), is a promising new candidate for the treatment of clear cell renal cell carcinoma (ccRCC). The company will present preclinical data at the European Cancer Congress 2015 (ECC2015) in Vienna on September 27 in a session starting at 16:45 CEST. In a poster titled “HIF-2α targeting with a novel RNAi delivery platform as therapy for renal cell carcinoma,” (abstract #353), Arrowhead scientists will show data suggesting that HIF-2α inhibition through RNA interference may significantly impact late stage ccRCC progression. The company is in the process of manufacturing scale up to allow for initiation of IND-enabling studies. Timing for anticipated regulatory submission will be declared in the future.
“Preclinical data using our new extrahepatic DPC™ delivery system has been very promising. We think the ability to target tissues outside of the liver, counting tumors, opens additional opportunities for Arrowhead to develop differentiated RNAi-therapeutics that address numerous diseases without adequate treatment options,” said Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer. “This is an important milestone for Arrowhead and we look forward to continued development of the DPC™ delivery platform and product candidates based on it.”
ARC-HIF2 is designed to inhibit the production of HIF-2α, which has been linked to tumor progression and metastasis in ccRCC. ARC-HIF2 employs a novel extrahepatic-targeted DPC™ that comprises a membrane active polymer to promote RNAi trigger endosomal release, an active ligand that targets the DPC™ to tumor cells, reversible masking to prevent polymer activity preceding to cellular uptake, and an RNAi trigger to HIF-2α conjugated directly to the DPC.
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
